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ABSTRACT 
 We consider nucleation of amyloid fibrils in the case when the process occurs by the 
mechanism of direct polymerization of practically fully extended protein segments, i.e. -
strands, into -sheets. Applying the classical nucleation theory, we derive a general 
expression for the work to form a nanosized amyloid fibril (protofilament) constituted of 
successively layered -sheets. Analysis of this expression reveals that with increasing its 
size, the fibril transforms from one-dimensional into two-dimensional aggregate in order to 
preserve the equilibrium shape corresponding to minimal formation work. We determine the 
size of the fibril nucleus, the fibril nucleation work and the fibril nucleation rate as explicit 
functions of the concentration and temperature of the protein solution. The results obtained 
are applicable to homogeneous nucleation which occurs when the solution is sufficiently pure 
and/or strongly supersaturated. 
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I. INTRODUCTION 
 Understanding the nucleation mechanism by which proteins assemble into highly 
ordered structures known as amyloid fibrils is a much-studied problem because of its 
implications for human health and nanotechnology. At present there are about 25 different 
disorders categorized as amyloid diseases including Alzheimer’s and Parkinson’s disease,1 
and the application of peptide building blocks in bio-sensors, tissue engineering, and 
antibacterial agents has recently been demonstrated.
2
 Structural studies
1,3
 have shown that 
amyloid fibrils formed by different proteins are composed of protofilaments that are wound 
together to form higher-order fibrillar structures. The protofilaments themselves are 
composed of several -sheet layers that share a common characteristic cross- structure. The 
application of electron and X-ray diffraction and of solid state NMR spectroscopy to 
microcrystals of various short peptide fragments and to amyloid fibrils also gives evidence of 
this structure.
4-8
 
 It is now well established that fibrillar protein aggregates form through a nucleation 
mechanism.
9-33
 Their formation kinetics is characterized by an initial lag time during which 
no aggregates are detected and a maximal rate of the overall aggregation process. Time-
resolved optical experiments that measure the fluorescence signal arising from dye molecules 
such as thioflavin-T bound to the protein aggregates enable determination of the lag time and 
the maximal aggregation rate. Interestingly, the product of these two quantities is nearly the 
same for a wide range of aggregation conditions and protein systems.
34,35
 So far, a 
considerable effort has been devoted to understanding how the amino acid sequence of 
proteins and the experimental conditions affect the kinetics of amyloid fibril formation.
30, 
32,33,36-44
 
 Experiments that investigate the physiochemical properties of the natural amino acids 
(such as -propensity, hydrophobicity, aromatic content and charge) have been used to 
substantiate phenomenological models able to predict changes in the aggregation rate upon 
mutation as well as to predict amino acid sequences of proteins, so-called hot spots, that are 
likely to belong to the fibril core.
45-50
 Although both the experimental studies and the 
theoretical models show that the kinetic parameters of aggregation depend strongly on the 
specificity of the amino acid sequence of the protein, it may be expected that this specificity 
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is a particular expression of a common fibril nucleation/growth mechanism which could be 
treated in the framework of existing general theories of nucleation and growth of new phases. 
 Treating protein aggregation as a nucleation-mediated process is necessarily based on 
the concept that the process is reversible. This is so, because nucleation can only occur in a 
metastable protein solution, and the solution metastability can only be defined by means of 
the protein equilibrium (or saturation) concentration at which the bulk protein phase neither 
grows nor dissolves in the solution. Below this concentration (known also as solubility) the 
solution is undersaturated so that nucleation and growth are impossible, and existing protein 
aggregates dissolve. Both experiments (e.g., Refs. 18,30,44,51-54) and computer simulations 
(e.g., Refs. 31,55) give evidence for the existence of equilibrium peptide concentration and 
for the dissolution of amyloid fibrils in sufficiently dilute solutions. Knowing the equilibrium 
concentration of monomeric peptide allows determination of the supersaturation for fibril 
nucleation, and the fibril dissolution demonstrates that fibril formation is not an irreversible 
process. 
 In this article, our objective is to apply the classical nucleation theory (CNT) (e.g., 
Refs. 56,57) and the recently proposed corrected CNT (CCNT)
58
 for describing the 
nucleation of amyloid fibrils by the mechanism of direct polymerization of practically fully 
extended protein segments, i.e. -strands, into -sheets. This mechanism is operative under 
conditions when no fibril precursors such as droplet-like peptide aggregates appear in the 
solution as a first step in the fibril nucleation process. By assuming that the nanosized 
amyloid fibril (protofilament) is built up of successively layered -sheets, we derive a 
general expression for the work to form such a fibril. This expression is used for 
determination of the size of the fibril nucleus, the fibril nucleation work and the fibril 
nucleation rate. The results obtained are applicable to homogeneous nucleation which occurs 
when the protein solution is sufficiently pure and/or strongly supersaturated. 
 
II. PHYSICAL MODEL 
 The model we propose is based on structural and morphological studies of amyloid 
fibrils and microcrystals,
4,5,7,8,52,59
 as well as on computer simulation results for amyloid fibril 
formation.
21-23,31,54
 Our considerations thus pertain to nanosized amyloid fibrils 
(protofilaments) built up of successively layered -sheets with fixed width and thickness. 
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Figure 1 schematizes such a fibril containing i such -sheets ( 1i ), each -sheet having m 
practically fully extended rod-like peptides ( 1m ) arranged parallel to each other and 
perpendicular to the fibril lengthening axis. The fibril is therefore prismatically shaped and 
contains a total of imn   peptides ( 1n ). The volume occupied by a peptide in the fibril is 
represented by that of right rectangular prism with cross-sectional area a0 (m
2
) and lateral 
areas a (m
2
) and ah (m
2
) of its two different side surfaces (Fig. 1). These areas are given by 
dda h0 , dda 0  and hh dda 0 , where dh (m) is the interpeptide distance in a -sheet, d 
(m) is the intersheet distance in the fibril, and d0 (m) is the extended peptide length, i.e. the -
sheet width. 
 Since the fibril is with fixed width equal to that of the constituting -sheets, it can be 
conceived as a two-dimensional (2D) phase in the m,i plane. The fibril is thus congenial with 
a 2D rectangularly shaped crystallite and its nucleation, lengthening along the m axis and 
thickening along the i axis could be described in the scope of existing crystal nucleation and 
growth theories (e.g., Refs. 56,57). Important parameters in these theories are the specific 
surface energies of the different crystal faces. For the fibril in Fig. 1, we denote by  (Jm2) 
and h (Jm
2
) the specific surface energies of the faces perpendicular to the m axis and the i 
axis, respectively. The third fibril specific surface energy, 0 (Jm
2
), is that of the fibril face 
in the m,i plane. However, knowing this energy is not necessary for the present 
considerations, because they are restricted to the earliest stage of fibril formation when the 
fibrils are so small that they change their size solely along the m and i axes. As they are then 
2D formations, 0 participates only implicitly, via the supersaturation  (J), in the 
description of their nucleation (see Section III). 
 By definition, the specific surface energy is equal to the work done on creating a unit 
area of the respective face by cutting the fibril along a plane parallel to the face and 
separating the resulting two half-fibrils far enough from each other. For that reason, the  
and h values are largely determined by the strength of the interpeptide bonds within the 
fibril. Whereas along the m axis the peptide bonding is dominated by the hydrogen bonds,
60
 
along the i axis the peptides (and, hence, the -sheets) are bound by much weaker bonds such 
as those due to the hydrophobic effect. Therefore, since to a first approximation the surface 
energy is proportional to the bond energy, the amyloid fibrils are characterized by the 
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important inequality  h . For example, we shall have 10/ h  or 20/  for fibrils 
with bond energy (per peptide) between two nearest-neighbor -sheets that is about 10 or 20 
times lower than the hydrogen bond energy between nearest-neighbor peptides in a -sheet. 
 
III. WORK OF FIBRIL FORMATION 
 At a given absolute temperature T (K) of the solution there exists a concentration Ce 
(m
3
) of peptide monomers, called the equilibrium concentration or solubility, at which a 
macroscopically large fibril neither grows nor dissolves. The solution is then saturated and 
fibril nucleation is impossible. When the actual concentration C1 (m
3
) of peptide monomers 
in the solution is lower or higher than Ce, the solution is undersaturated or supersaturated, 
respectively. While in the former case the system is in a thermodynamically stable state and 
fibril nucleation is again impossible, in the latter case the system is metastable and already 
able to nucleate fibrils that can grow up to macroscopic sizes. Using the physical model 
described above, we shall now determine the work Wi,m (J) to form a nanosized amyloid fibril 
of thickness i, length m and size imn   (n is the number of peptides constituting the fibril). 
 From nucleation theory (e.g., Refs. 56,57), the general expression for Wi,m is of the 
form  
 mifsmi imW ,, )(   ,         (1) 
where s (J) and f (J) are, respectively, the chemical potentials of a peptide in the solution 
and in the bulk fibrillar phase of which the fibril is the precursor, and mi,  (J) is the excess 
energy of the i,m-sized fibril. Physically, the first term on the right of Eq. (1) is the work 
gained from the assembling of n peptides into an n-sized fibril, and the second term is largely 
the work done on creating the fibril/solution interface. Determining mi,  is a hard physical 
problem, but with a relatively simple solution in the scope of CNT of crystals. According to 
this theory (e.g., Refs. 56,57), which we shall closely follow in the present study, mi,  is 
merely the total surface energy of the i,m-sized fibril so that it can be written down as 
 maiaima hhmi  222 00,  .        (2) 
Importantly, CNT neglects the possible dependence of 0,  and h on the fibril size. We 
note also that unlike the rigid crystallite, the fibril is a flexible formation which is why mi,  
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from Eq. (2) should include additional i,m-dependent terms accounting for the fibril bending, 
twisting and other likely deformations. However, if these terms are incorporated into the 
summands in Eq. (2), the equation will formally remain unchanged, but with generalized and 
possibly i,m-dependent fibril specific surface energies. Assuming that such a dependence is 
sufficiently weak, in the spirit of CNT we shall hereafter restrict our analysis to i,m-
independent 0,  and h. 
 Combining Eqs. (1) and (2), we obtain 
 maiaimW hhmi  22,  ,        (3) 
where the supersaturation 0 , defined by 
 002  afs  ,         (4) 
is the driving force for nucleation of 2D fibrils and their further growth in length and 
thickness, i.e. along the m and i axes. From Eq. (3) we thus find that the dimensionless work 
kTWw mimi /,,   to form an i,m-sized fibril is given by 
 misimw hmi  22,  ,         (5) 
where 0/  kTs   is the dimensionless supersaturation, k is the Boltzmann constant, and 
0/  kTa  and 0/  kTa hhh   are the dimensionless specific surface energies of 
the fibril faces perpendicular to the m axis and the i axis, respectively. Due to the much 
stronger hydrogen bonding in comparison with the hydrophobicity-mediated one, the 
inequality h   holds. As to s, Eqs. (A4) and (A9) in Appendix A show that it is given by 
)/ln( 1 eCCs   or TkTTLs e/  for solutions in which the supersaturation is experimentally 
controlled by C1 at a given T or by T at a given C1 [ TTT e   (K) is the undercooling, Te 
(K) is the solution equilibrium temperature, and L (J) is the latent heat or enthalpy (per 
peptide) of peptide aggregation]. 
 Most generally, the fibril can thicken at fixed length and lengthen at fixed thickness 
which is why in Eq. (5) i and m can be treated as independent variables. This makes it 
possible to use Eq. (5) for determination of the work to form an i-sheet of imn   peptides 
(the i-sheet is defined55 as a fibril with a fixed number i of successively layered, equally 
long -sheets in it). In particular, at 1i  we have mn   and from Eq. (5) we find that the 
formation of 1-sheet of n peptides, i.e. of a single n-sized -sheet, requires the work 
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  2)2(,1  nsw hn .                    (6) 
The straight lines 1 in Fig. 2 illustrate the n dependence of the 1-sheet formation work w1,n 
at scaled supersaturation 1/ hs  , 2 or 3 (as indicated). The lines are drawn according to 
Eq. (6) with h 10 . 
 Equation 6 is of special interest, for it reveals the conditions under which the 1-sheet 
can or cannot form spontaneously. As seen from this equation and the lowest line 1 in Fig. 
2, w1,n diminishes linearly with increasing the 1-sheet size n or, equivalently, length m when 
hs 2  which namely is the condition for spontaneous formation of 1-sheets. On the 
contrary, at those low supersaturations that satisfy the condition hs 2 , more and more 
work has to be done on the 1-sheet lengthening [w1,n from Eq. (6) then increases steadily 
with n; see the uppermost line 1 in Fig. 2]. Inasmuch as the fibril is the 1-sheet’s offspring, 
this implies that when hs 2 , the process of fibril formation is hampered by the existence 
of an energy barrier or, in other words, that it is nucleation-mediated. As visualized by the 
middle line 1 in Fig. 2, at the supersaturation 
 kTas hhh /221                      (7) 
the work w1,n from Eq. (6) does not change with the 1-sheet size n. Physically, this means 
that at s1 the 1-sheet is in thermodynamic equilibrium (or coexistence) with the solution. 
According to Eq. (7), s1 scales with the fibril “hydrophobic” specific surface energy h. 
 What is important about the 1-sheet is that it cannot grow unlimitedly as one-
dimensional (1D) formation, i.e. in length only. This is so, because when the 1-sheet is 
constituted of too many peptides, its total surface energy may already be higher than that of a 
2-sheet of the same size n. As at fixed n the fibril total surface energy has to be minimal, the 
most probable fibril shape will be the one that satisfies this thermodynamic requirement. This 
so-called equilibrium fibril shape is characterized by that value of the im ratio which fulfils 
the condition for extremum of wi,m from Eq. (5). Since this condition is of the form 
0// ,,  mwiw mimi  when i and m are treated as continuous variables, we readily find 
that the thickness i and the length m of an equilibrium-shaped n-sized fibril are not 
independent of each other, but interrelated by 
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  aami hhh ///  .                    (8) 
 This important equation is nothing else, but a form of the Gibbs-Curie-Wulff theorem 
for the equilibrium shape of crystals (e.g., Refs. 61,62). It parallels that found by Kaischew
63
 
for rectangularly shaped 2D crystals. Equation 8 explains why the fibrils depicted in Fig. 2a 
of Ref. 31 become increasingly elongated with increasing the energy that characterizes the 
peptide bonding along the fibril m axis. Indeed, since  or, equivalently,  is greater when 
this energy is higher, Eq. (8) predicts a smaller fibril thickness-to-length ratio. For instance, 
for fibrils with h 10  or h20 , the prediction is 10/1/ mi  or 20/1 , respectively. 
 We can now employ Eq. (5) to determine the dimensionless work kTWw nn /  to 
form an n-sized fibril with equilibrium shape [Wn (J) is the dimensional work for formation 
of such a fibril]. Using imn   and Eq. (8) yields 
 2/1)/(  ni h , 
2/1)/( hnm                    (9) 
so that, upon eliminating i and m from Eq. (5) with the help of these relations, we obtain 
( hn  / ) 
 2/12/1)(4 nsnw hn  .                  (10) 
This equation is of the form known from the classical theory of 2D nucleation (e.g., Ref. 56). 
Importantly, Eq. (10) is not valid for fibrils containing hn  /  peptides and having the 
equilibrium shape, because according to Eq. (9) such small fibrils would be with the 
physically meaningless thickness of 1i . This leads inescapably to the conclusion that the 
fibrils commence their ontogenesis as single -sheets, i.e. as 1D aggregates, and continue it 
as 2D formations with equilibrium shape only after reaching the supersaturation-independent 
transition size nt given by 
 hhht aan  //  .                  (11) 
For instance, fibrils characterized with 10/ h  or 20 will be single -sheets until they 
contain 10 tnn  or 20 peptides, respectively. The transition from 1D to 2D fibril 
geometry is clearly seen in Fig. 3 of Ref. 31. 
 Curves 1, 2 and 3 in Fig. 2 exhibit the dependence of the work wn to form a fibril of 
equilibrium shape on the fibril size n. They are drawn with the aid of Eq. (10) at 
10/  th n  and scaled supersaturation 1/ hs  , 2 or 3, respectively. The circles on the 
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curves mark the fibril transition at tnn   from single -sheet (1D aggregate) into fibril with 
equilibrium shape (2D aggregate). As seen from Fig. 2, beginning its growth as 1-sheet, the 
fibril cannot keep growing in the same way when tnn  , because this requires greater work 
(the dashed portions of straight lines 1) than the work (curves 1, 2 and 3) for its growth with 
equilibrium shape. Thus, the full size dependence of the fibril formation work is given by Eq. 
(6) in the small-size range ( tnn 1 ) and by Eq. (10) when the fibril size is large enough 
( tnn  ). Figure 2 reveals also that at any tnn   the work wn from Eq. (10) is smaller not 
only than the work w1,n from Eq. (6), but also than the work 
 inisw hni  2)/2(,                    (12) 
to form an i-sheet of the same number n of peptides and any given number ,...3,2,1i  of -
sheets. Equation (12) parallels that for 1D formation of condensed phases (e.g., Ref. 56). It 
follows from Eq. (5) upon replacing m by ni, and at 1i  it passes into Eq. (6). As visualized 
by the straight lines 2 and 3 in Fig. 2, given the i value, Eq. (12) predicts a linear 
dependence of wi,n on n. The lines are drawn by using this equation with 10/  th n , 
2i  or 3 and scaled supersaturation 1/ hs  , 2 or 3. It is seen that all these lines are above 
the curves depicting wn from Eq. (10) at the respective supersaturation. At a given s, 
successive portions of lines 1, 2 and 3 form in fact a broken straight line enveloping the 
corresponding wn curve. 
 Figure 2 shows also that at a certain s value the work w2,n does not change with n (the 
uppermost line 2 has no slope). This means that at this supersaturation no work is done on 
attaching or detaching peptides to or from a 2-sheet. Hence, regarded as a distinct peptide 
phase, the 2-sheet is then in equilibrium or coexistence with the solution. Similarly, if 
conceived as different peptide phases, the 3-, 4-, etc. sheets can coexist with the solution, 
but at different supersaturations which we shall denote by si. These coexistence 
supersaturations are readily obtained by setting equal to zero the bracketed factor in Eq. (12), 
because this factor is the driving force for i-sheet growth or dissolution. Doing that leads to 
the formula ( ,...3,2,1i ) 
 ikTais hhhi /2/2                     (13) 
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which shows that si decreases with increasing i-sheet thickness i. At 1i , i.e. for a single 
-sheet, si assumes its maximum value hs  21   from Eq. (7). Recalling that kTs /  
and employing Eqs. (A4) and (A9) in Eq. (13), we find that the equilibrium concentration Ci 
of peptide monomers and the equilibrium temperature Ti at which the i-sheet neither grows 
nor dissolves at a given T or C1, respectively, are of the form ( ,...3,2,1i ) 
 )/2exp( ikTaCC hhei                     (14) 
 )/21( iLaTT hhei   .                  (15) 
These expressions say that while Ci decreases, Ti increases with increasing the i-sheet 
thickness i. This behavior of Ci and Ti is in agreement with that seen in a peptide phase 
diagram obtained by kinetic Monte Carlo simulations of aggregation of -sheet forming 
peptides in solution.
55
 In the limit of i , i.e. when the i-sheet is sufficiently thick, Ci 
and Ti are equal to the equilibrium concentration Ce of peptide monomers and the 
equilibrium temperature Te that characterize the macroscopically large fibrillar phase. 
 
IV. NUCLEUS SIZE AND NUCLEATION WORK 
 Curve 1 in Fig. 2 depicts the change of wn with n when fibril formation is nucleation-
mediated and the fibrils have their equilibrium shape. It is seen that then wn passes through a 
maximum (marked by the star on curve 1) at a given fibril size n*. Thus, among the fibrils of 
different size, the n*-sized fibril is distinguishable with the greatest formation work. The 
fibril constituted of n* peptides is the so-called nucleus (or critical nucleus), and the work 
kTWww nn /* **   for its formation is the nucleation work. This quantity is important, 
because it determines the energy barrier kTww )*( 1,1  to nucleation of macroscopically large 
fibrils (the barrier magnitude at 1/ hs   is visualized by the double-headed arrow in Fig. 2). 
Treating n as a continuous variable and employing the condition for maximum, 
0)/( * nnn dndw , from Eq. (10) we find that the CNT nucleus size and nucleation work 
depend on the supersaturation according to ( hss  20 1  ) 
 22 )/(4/4* kTsaasn hhh                    (16) 
 skTaasw hhh
2)/(4/4*   .                 (17) 
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 These equations parallel those obtained by Kaischew
63
 for rectangularly shaped 2D 
crystals, and Eq. (16) is known as the Gibbs-Thomson equation (e.g., Ref. 56). We note that 
n* and w* are connected by the simple expression ** snw   and that they comply with the 
 form56,64,65 */* ndsdw   of the nucleation theorem. As the nucleus thickness i* and 
length m* are related by Eq. (8) which characterizes the fibril equilibrium shape, from 
*** min   and Eq. (16) it follows that ( hss  20 1  ) 
 kTsasi hhh /2/2*                     (18) 
 kTsasm /2/2*   .                  (19) 
 The dashed lines in Fig. 3 display the supersaturation dependence of i*, m*, n* and 
w*, predicted by the CNT Eqs. (16) – (19) at 10/  th n . As seen, all i*, m*, n* and w* 
decrease monotonically with increasing s. At the supersaturation hs  21   we have 1*i , 
th nnm   /**  and 1,1* ww   so that at this supersaturation the CNT nucleation barrier 
kTww )*( 1,1  vanishes. This means that in the supersaturation range hss  21   CNT is 
not applicable. Indeed, then fibril formation occurs barrierlessly (see the connected solid 
lines 1 and 3 in Fig. 2) and, also, Eq. (18) yields the physically irrelevant result 1*i . 
Thus, at the highest supersaturation s1 at which CNT is applicable, the CNT nucleus is a 
single -sheet, nt peptides in length, formed without any work for the attachment of 1tn  
peptides to the initial single peptide (see the middle line 1 in Fig. 2). 
 All of the above considerations are in the scope of CNT which provides a clear and 
mathematically simple description of the nucleation energetics. Recently, however, it has 
been shown
58
 that this theory may underestimate considerably the nucleation work of crystals 
and, as a consequence, overestimate by many orders of magnitude the crystal nucleation rate. 
In the case of 2D nucleation, the reason for this grave inaccuracy is that CNT disregards the 
work Wa (J) done on attaching the first molecule to the periphery of the crystal nucleus. This 
molecule triggers the propagation of a molecular row along the nucleus periphery and, 
thereby, the growth of the nucleus itself. We shall now apply CCNT
58
 in order to 
quantitatively improve the CNT Eqs. (16) and (17) for the fibril nucleus size and nucleation 
work. As to the CNT Eq. (10) for wn, CCNT does not provide a correction for it. 
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 Figure 4 illustrates the CNT and CCNT fibril nuclei at one and the same 
supersaturation. The CNT nucleus (Fig. 4a) can preserve its equilibrium shape solely by 
growing in both thickness and length. However, as discussed also by Zhang and 
Muthukumar,
31
 thickening is what actually impedes its growth because of the weak binding 
of the peptides to the surface of the nucleus outer -sheets, i.e. to the nucleus h-faces. The 
CNT nucleus needs just one more peptide (shown shaded in Fig. 4b) on one of these faces in 
order to be able to acquire barrierlessly the rest of the peptides necessary for the nucleus 
thickening by building-up of a new -sheet. Indeed, while on attaching one peptide to the 
nucleus h-face the work skT   is gained because of the peptide becoming part of the 
thermodynamically stable fibrillar phase, the work kTa  22   is spent due to the 
augmenting of the nucleus total surface area by the area 2a of the peptide two -faces (as 
seen in Fig. 4, in this process the peptide two h-faces do not contribute to the increase in the 
nucleus total surface area). Hence, the dimensionless overall peptide attachment work 
kTWw aa /  is 
 2 swa .                    (20) 
Subsequent attachment of a peptide to one of the -faces of the already attached first peptide 
does not change the nucleus total surface area so that in this process work is only gained, the 
gain being again  . Similarly, further successive lateral attachment of peptides is 
thermodynamically favored, because it requires no work to be done until the complete 
building-up of a whole new -sheet on the CNT nucleus. 
 It follows from the above that the CCNT fibril nucleus (Fig. 4b) is one peptide bigger 
than the CNT one (Fig. 4a) and that the CCNT nucleation work equals the CNT one plus the 
work for the first peptide attachment to a -sheet surface. Thus, in view of Eqs. (16), (17) 
and (20), the CCNT formulae for the supersaturation dependence of the fibril nucleus size 
and the fibril dimensionless nucleation work read ( hss  20 1  ) 
 1)/(41/4* 22  kTsaasn hhh                  (21) 
 kTasskTaassw hhh /2)/(42/4*
2   .              (22) 
 These formulae are a central result of the present study. Their applicability is 
restricted to the CNT supersaturation range ],0[ 1s , and Eq. (21) is the corrected Gibbs-
 13 
Thomson equation. In the  h  case Eqs. (21) and (22) pass into the CCNT ones for 2D 
nucleation of square-shaped crystals.
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  It can be readily verified that, as it should be, n* and 
w* from Eqs. (21) and (22) obey the nucleation theorem in the form
56,64,65
 */* ndsdw  . 
Also, it is seen that they are related by the simple formula 2)2*(*  snw . 
 The CCNT n*(s) and w*(s) dependences predicted by Eqs. (21) and (22) are 
represented in Fig. 3 by the solid lines n* and w*, respectively. We observe that while the 
CCNT correction has practically no effect on the CNT nucleus size, it affects strongly the 
CNT nucleation work. Importantly, while at 1ss   the CNT nucleation barrier vanishes, 
because at this supersaturation the CNT nucleation work w* from Eq. (17) equals w1,1, the 
CCNT nucleation barrier is still with the considerable height of kTh )(2    which is the 
difference between the CCNT w*kT from Eq. (22) and w1,1kT at 1ss  . CCNT thus predicts 
that fibril formation remains nucleation-mediated at supersaturations even higher than s1. 
However, at these high supersaturations fibril nucleation is non-classical, because 
considerations beyond the CNT requirement for equilibrium fibril shape are necessary for 
determination of the corresponding nucleation barrier and of the limiting supersaturation at 
which this barrier vanishes and above which fibril formation occurs barrierlessly, i.e. in the 
so-called metanucleation regime.
58
 
 
V. NUCLEATION RATE 
 In nucleation of fibrils in the volume of a supersaturated solution the nucleation rate J 
(m
3
 s
1
) is the frequency of appearance of supernucleus fibrils per unit solution volume. 
According to the classical Szilard-Farkas model of nucleation (e.g., Refs. 56,57), random 
attachment and detachment of single peptides, i.e. peptide monomers, to and from a 
subnucleus fibril is the mechanism by which this fibril may eventually grow bigger than the 
nucleus and become a supernucleus. This mechanism of direct polymerization leads to a 
simple expression for the nucleation rate when the solution supersaturation and temperature 
are kept constant. Then nucleation occurs in stationary regime and its time-independent or 
stationary rate J is given by the general formula (e.g., Refs. 56,57) 
 **CzfJ  .                    (23) 
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Here C* (m
3
) is the equilibrium concentration of fibril nuclei in the solution and f* (s
1
) is 
the frequency of attachment of peptide monomers to a nucleus. The numerical parameter 
1z  is the so-called Zeldovich factor which takes into account that C* is about twice the 
stationary concentration of nuclei and that not every attachment event results in overgrowth 
of the nucleus to a macroscopic size. For 2D nucleation, according to CNT in its self-
consistent formulation, z and C* are expressed as (e.g., Ref. 56) 
 2/1*)4/( nsz                     (24) 
 *)exp(* 1,11 wwCC                    (25) 
where w1,1 is the dimensionless work for monomer formation (the monomer is formally 
considered as the smallest representative of the nucleating phase). Equation (25) is often used 
in the equivalent form *)exp(* 0 wCC  , because C1, w1,1 and the concentration C0 (m
3
) of 
nucleation sites in the solution are related by the expression
56
 )exp( 1,101 wCC  . As to f*, it 
depends on the particular mechanism of monomer attachment to the nucleus. For instance, 
when the diffusion of monomer peptides toward the nucleus is fast enough, at the 
nucleus/solution interface there are always peptides ready to be incorporated into the nucleus 
by attaching themselves predominantly lengthwise, i.e. to the nucleus -faces. In this case, if 
f1 (s
1
) is the frequency of lengthwise attachment of monomer peptides to a single -sheet, f* 
is approximately given by 
 ** 1iff  ,                    (26) 
because a nucleus with thickness of i* -sheets has an i*-fold greater chance for such an 
attachment than a single -sheet. As it should be, at 1*i  Eq. (26) results in 1* ff  . The 
attachment frequency f1 itself is expected to be proportional to the concentration C1 of 
monomer peptide in the solution and to the factor )/exp( kTEa  in which Ea (J) is the 
activation energy for lengthwise attachment of a peptide to a single -sheet. 
  We can now obtain the CNT formula for the stationary rate J of fibril nucleation. 
Substituting z, C* and f* from Eqs. (24) – (26) in Eq. (23), accounting that in accordance 
with Eq. (6) we have )(21,1 hsw    and employing Eqs. (16) – (18), we arrive at the 
equation ( hss  20 1  ) 
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11
2/1
.               (27) 
 Using this equation should however be avoided, because it has been shown
58
 that it is 
highly inaccurate for crystals with dimensionless specific surface energy 1 . The 
quantitatively reliable formula for J is the CCNT one and, to find it, we use again Eq. (23) 
with C* from Eq. (25), but with w* from the CCNT Eq. (22). In addition, we employ the 
approximation 2/1z , because only half of the equilibrium nucleus concentration C* is 
effective in stationary nucleation
56
 and because after attaching a peptide, the CCNT nucleus 
virtually always grows to a macroscopically large size. Also, in accordance with Eq. (26), we 
approximate *f  by 12* ff  , since in most cases the CCNT nucleus is expected to be two 
-sheets thick (one -sheet plus one peptide on the sheet). Thus, with the aid of these 
approximations for z and f* and of the above expression for w1,1, we obtain the CCNT J(s) 
dependence in the form ( hss  20 1  ) 
 






s
CsfJ hh


4
2exp)( 11 .                 (28) 
 Comparing J from Eqs. (27) and (28), we see that the CCNT nucleation rate is much 
lower that the CNT one, because the exponential function in Eq. (28) does not contain the 
summand s2  in which kTa /   is usually much greater than unity (see below). The 
absence of this summand cannot be compensated by the absence in Eq. (28) of the factor 
2/1)4/(  sh  which is typically a number between 0.01 and 0.1. Like Eq. (27), Eq. (28) is 
applicable in the CNT supersaturation range ],0[ 1s . 
 When T is fixed and s is controlled by means of the concentration C1 of monomer 
peptide, we have )/ln( 1 eCCs   and ee CCff /1,11   (the attachment frequency f1,e (s
1
) is 
proportional to )/exp( kTEa  and is the value of f1 at the equilibrium concentration Ce of 
monomer peptide, i.e. at 0s ). From Eq. (28) it then follows that the J(C1) dependence is of 
the form ( )/2exp(/1 1 kTaCC hhe  ) 
 )]/ln(/exp[)/()( 1
2
11 ee CCBCCACJ  ,                (29) 
where the C1-independent kinetic factor A (m
3
 s
1
) and the dimensionless thermodynamic 
parameter B are given by 
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 )/2exp(,1 kTaCfA hhee                    (30) 
 2)/(4 kTaaB hh .                   (31) 
Taking the logarithm of both sides of Eq. (29), differentiating with respect to 1lnC  and 
accounting that the CCNT nucleus size n* is given by Eq. (21), we find that 
 1)(ln/)(ln)(* 11  CdJdCn .                 (32) 
This important formula shows that when available isothermal J(C1) data are plotted in Jln -
vs.- 1lnC  coordinates, the slope of the resulting line is a direct measure of the nucleus size. 
Equation (32) parallels that in Ref. 13 and, as can be readily verified, it holds true also for the 
CNT n* and J from Eqs. (16) and (27). This is so, because Eq. (32) is in fact a general result 
following from application of the nucleation theorem to isothermal nucleation of condensed 
single-component phases.
56,64,65
 Given isothermal J(C1) data, Eq. (32) thus allows a theory-
independent experimental determination of the nucleus size as a function of the concentration 
of monomer peptide in the solution and verification of any formula for the supersaturation 
dependence of n*, e.g., the corrected Gibbs-Thomson Eq. (21) of CCNT. Naturally, a more 
accurate determination of n* requires replacement of C1 in Eq. (32) by the peptide activity. 
 In the other case of experimental interest, the case when s is controlled with the aid of 
T at fixed C1, the proportionality of f1 to )/exp( kTEa  can be expressed as 
)/exp(01 kTEff a , where the virtually T-independent frequency factor f0 (s
1
) is 
proportional to C1. As then TkTTLs e/ , Eq. (28) results in the following J(T) dependence 
( LTaT ehh /20  ): 
 )/exp()/exp()( TTBkTEATJ  .                (33) 
Here the kinetic factor A (m
3
 s
1
), the thermodynamic parameter B (K
2
) and the effective 
activation energy E (J) are specified by 
 10CfA                      (34) 
 kLTaaB ehh /4                     (35) 
 hha aEE 2 ,                   (36) 
and it should be kept in mind that Eq. (33) is applicable provided the peptides remain in 
extended conformation in the entire temperature range studied (then all three parameters A, B 
and E in the equation can be treated as practically T-independent). 
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 Equations (28), (29) and (33) are also a central result of the present study. The 
concentration dependence of J from Eq. (29) is illustrated in Fig. 5 by the solid line. The line 
is drawn by using this equation with 12/  kTa  and 10/ aa hh  , the latter implying 
2.1/  hhh kTa  . The value of  is obtained with 300T  K, 5a  nm
2
 and 10  
mJm2, a specific surface energy in the range of 0.1–30 mJm2 reported for protein crystals in 
aqueous solutions.
30,66-73
 The a value follows from dda 0  with 50 d  nm and 1d  nm.
 
21,23
 
 As seen from Fig. 5, the monotonic increase of J with C1 is much faster at lower 
concentrations of monomer peptide than at those close to the concentration 
)/2exp(1 kTaCC hhe    corresponding to the maximal supersaturation )/ln( 11 eCCs    of 
CNT and CCNT applicability. This behavior of J is due to the considerable diminishing of 
the nucleation work w* and the nucleus size n* with the supersaturation )/ln( 1 eCCs   
approaching s1. The numbers at the circles on line CCNT in Fig. 5 indicate the CCNT n* 
values following from Eq. (21) at the corresponding supersaturations. For comparison 
between CCNT and CNT, the dashed line in Fig. 5 depicts the CNT isothermal nucleation 
rate J from Eq. (27) (with 
s
eefCf
2
,111  , )/ln( 1 eCCs  , 12  and 2.1h ), and the 
numbers at the circles on the line indicate the corresponding CNT nucleus size n* from Eq. 
(16). We observe that at the exemplified values of  and h the CNT nucleation rate is about 
11 orders of magnitude higher than the CCNT one. This spectacular overestimation is almost 
entirely due to the CNT underestimation of the nucleation work w* (see Fig. 3), because the 
pre-exponential factors in Eqs. (27) and (28) differ by about one order of magnitude only. As 
to the eeCf ,1  product which scales J in Fig. 5, it may have values in a range which is orders-
of-magnitude wide, because ef ,1  can hardly be higher than the attachment frequency of 10

 
s
1
 encountered in nucleation of inorganic crystals in solutions (e.g., Refs. 56,57), but can 
easily be as low as the attachment frequency of 10
4
 s
1
 inferred from measured rates of fibril 
elongation.
74
 Hence, with exemplifying 2010eC  m
3
 (i.e. 1.5 M), it may be expected that 
in many cases of homogeneous nucleation the product f1,eCe is from 10
16
 to 10
25
 m
3
 s
1
. This 
product can, however, be several orders of magnitude smaller for peptides with considerably 
inhibited solubility and/or ability of lengthwise attaching to -sheets. 
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VI. CONCLUSION 
 The analysis made shows that application of existing general theories of nucleation of 
new phases to amyloid fibril nucleation by the mechanism of direct polymerization can 
supply valuable information about both the thermodynamics and the kinetics of the process. 
The modeling of the nanosized amyloid fibrils (protofilaments) by prismatic aggregates with 
fixed width, changing thickness determined by the number of successively layered -sheets 
in them, and changing length equal to the number of peptides in a -sheet leads to the general 
CNT formula, Eq. (5), for the work to form a fibril of given size. This work is expressed by 
Eq. (12) when the fibril evolves with constant number of constituent -sheets and by Eq. (10) 
when it preserves equilibrium shape during its evolution. Due to the impossibility of the 
smallest fibrils to be less than one -sheet thick, a fibril first develops as an 1D aggregate and 
becomes a 2D one only later, after reaching the transition size nt given by Eq. (11). Both the 
transition size and the equilibrium shape of the bigger fibrils are controlled by the ratio of the 
specific surface energies  and h of the fibril faces normal to the fibril elongation and 
thickening axes. These energies affect also the fibril nucleus size n* and nucleation work w* 
whose CNT dependences on the supersaturation s are given by Eqs. (16) and (17). The 
corresponding CCNT dependences are given by Eqs. (21) and (22) and have always to be 
used for a more accurate determination of n* and, especially, of w*. Importantly, CCNT 
predicts that fibril formation remains nucleation-mediated at supersaturations even higher 
than the supersaturation s1 at which the CNT nucleation barrier vanishes. At these high 
supersaturations, however, fibril nucleation is non-classical, because the respective 
nucleation barrier cannot be determined with the help of the CNT requirement for 
equilibrium shape. Equations (21) and (22) show that changes in  and/orh brought about, 
e.g., by alteration of the solution ionic strength, adsorption of impurity molecules on the fibril 
faces or mutations along the peptide chain may cause significant changes in n* and w* and, 
thereby, in the fibril nucleation kinetics. 
 The kinetics of stationary fibril nucleation is characterized by the nucleation rate J 
which is determined much more accurately by CCNT than by CNT because of the adequate 
calculation of the fibril nucleation work w*. The general CCNT dependence of J on the 
supersaturation s is represented by Eq. (28), and the particular CCNT dependences of J on 
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the solution concentration C1 or temperature T are expressed by Eqs. (29) and (33). The 
nucleation rate is an exponentially strong function of s because of the s-dependent barrier to 
fibril nucleation in the supersaturation range ],0[ 1s  of applicability of these equations. In 
isothermal nucleation, Eq. (32) allows a theory-independent determination of the number n* 
of peptides in the fibril nucleus from the slope of the line representing experimental J(C1) 
data in double logarithmic coordinates. 
 The results obtained are applicable to homogeneous amyloid fibril nucleation which 
can occur when the protein solution is sufficiently pure and/or strongly supersaturated. As in 
the classical theory of nucleation (e.g., Refs. 56,57), they need appropriate modification in 
order to be used in the case of heterogeneous nucleation which takes place on nucleation-
active sites provided by foreign agents such as impurity nanoparticles within the solution 
(e.g., Refs. 26,75) and/or by foreign surfaces contacting the solution. 
 Currently, open questions in nucleation of amyloid fibrils are, e.g., the surface 
energies and the equilibrium shape of the fibrils, the size of the nucleus fibril, the magnitude 
of the nucleation barrier, the mechanism of peptide attachment to the fibrils and, most 
importantly, the dependence of the nucleation rate on the peptide concentration and solution 
temperature. The analysis made offers answers to some of these questions and the results 
obtained in the paper could be a helpful guide in studying the intriguing phenomenon of 
amyloid fibril nucleation. 
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APPENDIX A: THE SUPERSATURATION 
 In experiments on protein aggregation, the supersaturation  is usually controlled 
either by the concentration of monomer protein at a fixed solution temperature (e.g., Refs. 9-
14,16-18,29,30,33,36,38,44,52-54,68,70) or by the temperature at a fixed protein 
concentration (e.g., Refs. 9,10,14,19,25,26,70,74,76). 
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 To express  from Eq. (4) in terms of the concentration C1 of monomer peptide at a 
fixed temperature T we recall that when the solution is sufficiently dilute, 
thermodynamically, s and C1 are related by (e.g., Refs. 56,57) 
 )/ln( 1 rrs CCkT  .                 (A1) 
Hence,  from Eq. (4) becomes 
 )(2)()/ln()( 100111 CaCCCkTC frr   .              (A2) 
The C1-independent reference chemical potential r, the reference concentration Cr and the f 
and 0 terms can be eliminated with the help of the equation 
 )(2)()/ln(0 00 eefrer CaCCCkT                  (A3) 
which follows from Eq. (A2) upon taking into account that there is no driving force for fibril 
nucleation and growth when the solution is saturated [then C1 equals the equilibrium 
concentration (or solubility) Ce  of monomer peptide at which, by definition, 0 ]. Since 
the chemical potential f of the peptides in the bulk fibrillar phase is practically C1-
independent and the 0(C1) dependence may be negligible, by subtracting Eq. (A3) from Eq. 
(A2) and using the approximations 0)()( 1  eff CC   and 0)()( 010  eCC  , we obtain 
the known (C1) formula for nucleation of condensed phases in solutions (e.g., Refs. 56,57) 
 )/ln()( 11 eCCkTC  .                 (A4) 
We note, however, that for more concentrated peptide solutions a more accurate evaluation 
of  requires replacing the concentrations in Eq. (A4) by the corresponding activities.56,57 
Also, in some cases the neglected term )]()([2 0100 eCCa    may need accounting for as a 
summand in the right-hand side of Eq. (A4). 
 In studying fibril nucleation and growth it is also important to know how  varies 
with changing the solution temperature T at a fixed monomer peptide concentration C1. Then 
an approximate formula for the (T) dependence can be obtained from Eq. (4) with 
accounting for the thermodynamic relations 
 Tsssrs  ,                   (A5) 
 Ts ffrf  ,                   (A6) 
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which are valid when the entropies ss and sf per peptide in, respectively, the solution and the 
bulk fibrillar peptide phase are practically T-independent in the temperature range studied. 
Combining Eqs. (4), (A5) and (A6) yields 
 )(2)()( 00,, TaTssT fsfrsr   .               (A7) 
Similar to Eq. (A2), the T-independent reference chemical potentials r,s and r,f as well as 
the 0 term can be eliminated by using the equation 
 )(2)(0 00,, eefsfrsr TaTss                  (A8) 
which expresses the fact that the solution is saturated ( 0 ) at the equilibrium 
temperature Te (by definition, at eTT   the macroscopically large fibrillar phase coexists 
with the solution). Since to a first approximation 0 can be treated as T-independent, 
subtracting Eq. (A8) from Eq. (A7) and using the approximation 0)()( 00  eTT   leads to 
the formula 
 TTLT e  )/()(                   (A9) 
in which efs TssL )(   (in J) is the latent heat or enthalpy (per peptide) of fibril formation, 
and TTT e  , when positive, is the experimentally controlled undercooling. We note that 
Eq. (A9) parallels the known (T) dependence for crystal nucleation in melts (e.g., Ref. 56). 
Naturally, a more accurate determination of  requires allowing for the temperature 
dependence of the entropies ss and sf (Ref. 56) or, equivalently, of the latent heat L of peptide 
fibrillation. Also, in some cases the neglected term )]()([2 000 eTTa    may need 
accounting for as a summand in the right-hand side of Eq. (A9). 
 Being expressed via quantities that refer to the equilibrium between two bulk phases, 
the solution and the macroscopically large fibrillar phase, the latent heat L of fibril formation 
is a well-defined parameter independent of the fibril length and/or thickness. In both real and 
computer experiments L can be determined by plotting solubility-vs-temperature data in 
lnCe-vs-(1/T) coordinates.
31,54,55
 If L is T-independent, the resulting line is straight, and the L 
value is obtainable from the slope of this line. Experiments on peptide solubility
54
 reveal that 
Ce may pass through a minimum at a certain temperature. The descending and ascending 
portions of the Ce(T) line correspond to negative and positive L, respectively. Computer 
simulations
31,55
 show that in the temperature range in which the peptide molecules in the 
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solution are practically fully unfolded (stretched) and form -sheets, L is positive and 
practically T-independent. In this case, since nucleation and growth are possible only for 
0 , T is positive and is called the undercooling (as done in the present paper). When 
protein aggregation is to occur in a temperature range in which L is negative (e.g., Refs. 
54,76), T has to be negative in order to ensure that 0  and for that reason it then 
acquires the physical meaning of overheating. It is important to note also that knowing Ce as 
a function of T allows determining the (T) dependence more accurately than by Eq. (A9). 
Indeed, substitution of the Ce(T) function in Eq. (A4) results in 
 )](/ln[)( 1 TCCkTT e                (A10) 
where now C1 is fixed. Albeit implicitly, through the known dependence of Ce on T, this 
equation automatically takes into account the temperature dependence and the sign of the 
latent heat L of protein aggregation. As can be readily verified, Eq. (A10) simplifies to Eq. 
(A9) when L is T-independent, because then Ce obeys the integrated van’t Hoff equation 
 



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
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

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


TTk
L
CTC
e
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11
exp)( 1                (A11) 
which corresponds to integration condition 1)( CTC ee  . Naturally, the applicability of Eq. 
(A10) is restricted to sufficiently dilute protein solutions. For more concentrated solutions, C1 
and Ce in Eq. (A10) should be replaced by the respective activities. 
 Finally, it is worth noting that, experimentally, factors as the solvent and the solution 
pH can also be used to control the protein aggregation and dissolution (e.g., Refs. 54,76). 
When these or other factors affect the equilibrium concentration Ce of the protein monomers 
and the solution is sufficiently dilute, Eq. (A4) or Eq. (A10) allow determination of the 
solution supersaturation at the corresponding C1 and T. 
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Figure 1 Schematic of nanosized amyloid fibril (protofilament) with thickness of i -sheets 
and length of m peptides. Only the uppermost of the four -sheets in the fibril and the 
rightmost of the m consecutively aligned peptides in this -sheet are labeled. The ’s are the 
specific surface energies of the three fibril faces, and the a’s are the areas of the three peptide 
faces. 
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Figure 2 Size dependence of the work wi,n to form 1-sheet, 2-sheet and 3-sheet 
[according to the CNT Eq. (12), the straight lines] and the work wn to form a fibril with 
equilibrium shape [according to the CNT Eq. (10), the curves] at 10/ h  and scaled 
supersaturation 1/ hs  , 2 or 3 (as indicated). The double-headed arrow visualizes the 
height of the nucleation barrier at the nucleus size n*, the circles on the solid lines 
correspond to the transition size nt, and the star on line 1 indicates the maximum of wn.  
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Figure 3 Supersaturation dependence of the nucleation work w* and of the thickness i*, 
length m* and size n* of the fibril nucleus at 10/ h : solid lines – according to the 
CCNT Eqs. (21) and (22); dashed lines – according to the CNT Eqs. (16) – (19). The arrow 
indicates the maximum scaled supersaturation hs  /1  of applicability of both CCNT and 
CNT. 
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Figure 4 Cross section of (a) CNT nucleus and (b) CCNT nucleus. The section is parallel to 
the m,i plane in Fig. 1, and the shaded rectangle schematizes the peptide that triggers the 
spreading of a new -sheet on one of the nucleus h-faces. 
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Figure 5 Dependence of the fibril nucleation rate J on the concentration C1 of monomer 
peptide at 12  and 10/ h : solid line – the CCNT Eq. (29); dashed line – the CNT 
Eq. (27). The arrow points to the maximum supersaturation s1 of applicability of both CCNT 
and CNT, and the numbers at the circles on the lines indicate the number of peptides in the 
CCNT or CNT fibril nucleus at the corresponding concentration. 
 
 
 
